Attenuation of morphine antinociceptive tolerance by a CB1 receptor agonist and an NMDA receptor antagonist: Interactive effects

Neuropharmacology

Volumn 58, Issue 2, 2010, Pages 544-550

  Fischer, Bradford D ^a,c   Ward, Sara J ^d   Henry, Fredrick E ^a   Dykstra, Linda A ^a,b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TEMPLE UNIVERSITY   (United States)

Author keywords

Antinociception; Cannabinoid; CB1; Dose addition; Morphine; NMDA; Tolerance

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; MORPHINE SULFATE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG POTENTIATION; HOT PLATE TEST; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; HOT TEMPERATURE; ISOQUINOLINES; MALE; MICE; MICE, INBRED C57BL; MORPHINE; PAIN; PAIN MEASUREMENT; RECEPTOR, CANNABINOID, CB1; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 72049125608     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.08.005     Document Type: Article

References (45)

1. Adam F., Bonnet F., and Le Bars D. Tolerance to morphine analgesia: evidence for stimulus intensity as a key factor and complete reversal by a glycine site-specific NMDA antagonist. Neuropharmacology 51 (2006) 191-202
2. Adam F., Dufour E., and Le Bars D. The glycine site-specific NMDA antagonist (+)-HA966 enhances the effect of morphine and reverses morphine tolerance via a spinal mechanism. Neuropharmacology 54 (2008) 588-596
3. Allen R.M., and Dykstra L.A. Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-d-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude. J. Pharmacol. Exp. Ther. 295 (2000) 1012-1021
4. Allen R.M., Carelli R.M., Dykstra L.A., Suchey T.L., and Everett C.V. Effects of the competitive N-methyl-d-aspartate receptor antagonist, LY235959 [(-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid], on responding for cocaine under both fixed and progressive ratio schedules of reinforcement. J. Pharmacol. Exp. Ther. 315 (2005) 449-457
5. Allen R.M., Uban K.A., Atwood E.M., Albeck D.S., and Yamamoto D.J. Continuous intracerebroventricular infusion of the competitive NMDA receptor antagonist, LY235959, facilitates escalation of cocaine self-administration and increases break point for cocaine in Sprague-Dawley rats. Pharmacol. Biochem. Behav. 88 (2007) 82-88
6. Alger B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol. 68 (2002) 247-286
7. Auclair N., Otani S., Soubrie P., and Crepel F. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J. Neurophysiol. 83 (2000) 3287-3293
8. Bhargava H.N. Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice. Psychopharmacology (Berl.) 49 (1976) 267-270
9. Brown S.P., Safo P.K., and Regehr W.G. Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels. J. Neurosci. 24 (2004) 5623-5631
10. Chapman C.R., Casey K.L., Dubner R., Foley K.M., Gracely R.H., and Reading A.E. Pain measurement: an overview. Pain 22 (1985) 1-31
11. Cichewicz D.L., and Welch S.P. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 305 (2003) 812-817
12. De Vry J., Denzer D., Reissmueller E., Eijckenboom M., Heil M., Meier H., and Mauler F. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. J. Pharmacol. Exp. Ther. 310 (2004) 620-632
13. Dubner R., and Ren K. Assessing transient and persistent pain in animals. In: Wall P.D., and Melzack R. (Eds). Textbook of Pain (1999), Churchill Livingstone, Edinburgh, UK 359-369
14. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83 (2003) 1017-1066
15. Fischer B.D., and Dykstra L.A. Interactions between an NMDA antagonist and low-efficacy opioid receptor agonists in assays of schedule-controlled responding and thermal nociception. J. Pharmacol. Exp. Ther. 318 (2006) 1300-1306
16. Fischer B.D., Zimmerman E.I., Picker M.J., and Dykstra L.A. Morphine in combination with metabotropic glutamate receptor antagonists on schedule-controlled responding and thermal nociception. J. Pharmacol. Exp. Ther. 324 (2008) 732-739
17. Godino M.C., Torres M., and Sánchez-Prieto J. CB1 receptors diminish both Ca(2+) influx and glutamate release through two different mechanisms active in distinct populations of cerebrocortical nerve terminals. J. Neurochem. 101 (2007) 1471-1482
18. Hine B., Friedman E., Torrelio M., and Gershon S. Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science 187 (1975) 443-445
19. Inoue M., Mishina M., and Ueda H. Locus-specific rescue of GluRepsilon1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence. J. Neurosci. 23 (2003) 6529-6536
20. Kozela E., Pilc A., and Popik P. Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-d-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Psychopharmacology (Berl.) 165 (2003) 245-251
21. Kreitzer A.C., and Regehr W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29 (2001) 717-727
22. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Böhme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., and Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
23. Lichtman A.H., Sheikh S.M., Loh H.H., and Martin B.R. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J. Pharmacol. Exp. Ther. 298 (2001) 1007-1014
24. Mendez I.A., and Trujillo K.A. NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats. Psychopharmacology (Berl.) 196 (2008) 497-509
25. Nabeshima T., Mouri A., Murai R., and Noda Y. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. Ann. N. Y. Acad. Sci. 1086 (2006) 160-168
26. Navarro M., Chowen J., Carrera M.R.A., del Arco I., Villanua M.A., Martin Y., Roberts A.J., Koob G.F., and Rodriguez de Fonseca F. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 9 (1998) 3397-3402
27. Newcomer J.W., and Krystal J.H. NMDA receptor regulation of memory and behavior in humans. Hippocampus 11 (2001) 529-542
28. Ohno-Shosaku T., Tsubokawa H., Mizushima I., Yoneda N., Zimmer A., and Kano M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J. Neurosci. 22 (2002) 3864-3872
29. Ohno-Shosaku T., Maejima T., and Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29 (2001) 729-738
30. Pelissier T., Infante C., Constandil L., Espinosa J., Lapeyra C.D., and Hernández A. Antinociceptive effect and interaction of uncompetitive and competitive NMDA receptor antagonists upon capsaicin and paw pressure testing in normal and monoarthritic rats. Pain 134 (2008) 113-127
31. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 63 (2001) 569-611
32. Rawls S.M., Cowan A., Tallarida R.J., Geller E.B., and Adler M.W. N-Methyl-d-aspartate antagonists and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1-i, j]quinolin-6-one], a cannabinoid agonist, interact to produce synergistic hypothermia. J. Pharmacol. Exp. Ther. 303 (2002) 395-402
33. Robinson L., McKillop-Smith S., Ross N.L., Pertwee R.G., Hampson R.E., Platt B., and Riedel G. Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats. Psychopharmacology (Berl.) 198 (2008) 551-563
34. Smith P.A., Selley D.E., Sim-Selley L.J., and Welch S.P. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur. J. Pharmacol. 571 (2007) 129-137
35. Soria G., Mendizábal V., Touriño C., Robledo P., Ledent C., Parmentier M., Maldonado R., and Valverde O. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 30 (2005) 1670-1680
36. Stevenson G.W., Folk J.E., Linsenmayer D.C., Rice K.C., and Negus S.S. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception. J. Pharmacol. Exp. Ther. 307 (2003) 1054-1064
37. Stevenson G.W., Folk J.E., Rice K.C., and Negus S.S. Interactions between δ and μ opioid agonists in assays of schedule-controlled responding, thermal nociception, drug self-administration, and drug versus food choice in rhesus monkeys: studies with SNC80 [(+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N, N-diethylbenzamide] and heroin. J. Pharmacol. Exp. Ther. 314 (2005) 221-231
38. Tallarida R.J. Drug Synergism and Dose-effect Data Analysis (2000), Chapman & Hall/CRC Press, Boca Raton, FL
39. Tallarida R.J. The interaction index: a measure of drug synergism. Pain 98 (2002) 163-168
40. Tallarida R.J., Kimmel H.L., and Holtzman S.G. Theory and statistics of detecting synergism between two active drugs: cocaine and buprenorphine. Psychopharmacology (Berl.) 133 (1997) 378-382
41. Trujillo K.A. Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies. Psychopharmacology (Berl.) 151 (2000) 121-141
42. Ujike H., and Morita Y. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J. Pharmacol. Sci. 96 (2004) 376-381
43. Vela G., Ruiz-Gayo M., and Fuentes J.A. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 34 (1995) 665-668
44. Ward S.J., Lefever T.W., Jackson C., Tallarida R.J., and Walker E.A. Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice. J. Pharmacol. Exp. Ther. 325 (2008) 567-576
45. Wise L.E., Iredale P.A., and Lichtman A.H. The cannabinoid CB(1) receptor antagonist CE prolongs spatial memory duration in a rat delayed radial arm maze memory task. Eur. J. Pharmacol. 590 (2008) 246-249